Aflibercept Intravitreous Injection
ApprovedRecruiting 0 watching 0 views this week🔥 Hot
82
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Polypoidal Choroidal Vasculopathy (PCV)
Conditions
Polypoidal Choroidal Vasculopathy (PCV), Neovascular Age Related Macular Degeneration (AMD)
Trial Timeline
Jan 1, 2026 → Dec 31, 2027
NCT ID
NCT07365371About Aflibercept Intravitreous Injection
Aflibercept Intravitreous Injection is a approved stage product being developed by Bayer for Polypoidal Choroidal Vasculopathy (PCV). The current trial status is recruiting. This product is registered under clinical trial identifier NCT07365371. Target conditions include Polypoidal Choroidal Vasculopathy (PCV), Neovascular Age Related Macular Degeneration (AMD).
Hype Score Breakdown
Clinical
30
Activity
20
Company
7
Novelty
10
Community
12
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07365371 | Approved | Recruiting |
Competing Products
9 competing products in Polypoidal Choroidal Vasculopathy (PCV)
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Zimura + Eylea | Astellas Pharma | Phase 2 | 52 |
| Avacincaptad Pegol | Astellas Pharma | Phase 2 | 52 |
| Verteporfin Photodynamic Therapy + Ranibizumab | Novartis | Approved | 85 |
| Brolucizumab 6mg + Brolucizumab 6mg | Novartis | Phase 3 | 77 |
| Intravitreal aflibercept injection 2.0mg | Regeneron Pharmaceuticals | Approved | 84 |
| Rescue Intravitreal Aflibercept Injection | Regeneron Pharmaceuticals | Approved | 84 |
| aflibercept 8 mg | Bayer | Phase 3 | 74 |
| aflibercept | Bayer | Approved | 82 |
| ranibizumab intravitreal injection | Pacific Biosciences | Phase 1 | 25 |